Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure

Spontaneously mutant selection

Sabina C. Righetti, Paola Perego, Elisabetta Corna, Marco A. Pierotti, Franco Zunino

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We have previously shown that p53 mutations are associated with cisplatin resistance in ovarian carcinoma IGROV-1/Pt 1 cells. The relationship between p53 status and the development of resistance has not been completely elucidated; in particular, the biological mechanisms behind the acquired drug-resistant p53-mutant phenotype were not clearly explained. Thus, in this study, we investigated whether the p53 mutations found in IGROV-1/Pt 1 cells (270 and 282 codons) resulted from selection, under the selective pressure of the cytotoxic treatment, of a spontaneously mutant cell population preexistent in the cisplatin-sensitive parental cell line (IGROV- 1) or were induced by drug (genotoxic) treatment. For this purpose, an allele-specific PCR approach was used. Primers carrying the desired mutations (T→A codon 270, C→T codon 282) in the 3' terminus, and the corresponding wild-type primers were used to amplify genomic DNA from the original IGROV-1 cell line used to select the mutant IGROV-1/Pt 1. To increase sensitivity, we hybridized blots of the PCRs with the radiolabeled PCR fragment from IGROV- 1/Pt 1. Amplification was obtained for IGROV-1 DNA with the mutated allele- specific primers, indicating the preexistence of a mutated population in the IGROV-1 cell line. Titration experiments suggested that the frequency of the mutated alleles was

Original languageEnglish
Pages (from-to)473-478
Number of pages6
JournalCell Growth and Differentiation
Volume10
Issue number7
Publication statusPublished - Jul 1999

Fingerprint

Codon
Cisplatin
Carcinoma
Cell Line
Polymerase Chain Reaction
Mutation
Alleles
Pharmaceutical Preparations
DNA
Gene Frequency
Population
Phenotype
TA 270

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology

Cite this

Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure : Spontaneously mutant selection. / Righetti, Sabina C.; Perego, Paola; Corna, Elisabetta; Pierotti, Marco A.; Zunino, Franco.

In: Cell Growth and Differentiation, Vol. 10, No. 7, 07.1999, p. 473-478.

Research output: Contribution to journalArticle

Righetti, Sabina C. ; Perego, Paola ; Corna, Elisabetta ; Pierotti, Marco A. ; Zunino, Franco. / Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure : Spontaneously mutant selection. In: Cell Growth and Differentiation. 1999 ; Vol. 10, No. 7. pp. 473-478.
@article{e2071cf8531243e298f208d2c14cac08,
title = "Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: Spontaneously mutant selection",
abstract = "We have previously shown that p53 mutations are associated with cisplatin resistance in ovarian carcinoma IGROV-1/Pt 1 cells. The relationship between p53 status and the development of resistance has not been completely elucidated; in particular, the biological mechanisms behind the acquired drug-resistant p53-mutant phenotype were not clearly explained. Thus, in this study, we investigated whether the p53 mutations found in IGROV-1/Pt 1 cells (270 and 282 codons) resulted from selection, under the selective pressure of the cytotoxic treatment, of a spontaneously mutant cell population preexistent in the cisplatin-sensitive parental cell line (IGROV- 1) or were induced by drug (genotoxic) treatment. For this purpose, an allele-specific PCR approach was used. Primers carrying the desired mutations (T→A codon 270, C→T codon 282) in the 3' terminus, and the corresponding wild-type primers were used to amplify genomic DNA from the original IGROV-1 cell line used to select the mutant IGROV-1/Pt 1. To increase sensitivity, we hybridized blots of the PCRs with the radiolabeled PCR fragment from IGROV- 1/Pt 1. Amplification was obtained for IGROV-1 DNA with the mutated allele- specific primers, indicating the preexistence of a mutated population in the IGROV-1 cell line. Titration experiments suggested that the frequency of the mutated alleles was",
author = "Righetti, {Sabina C.} and Paola Perego and Elisabetta Corna and Pierotti, {Marco A.} and Franco Zunino",
year = "1999",
month = "7",
language = "English",
volume = "10",
pages = "473--478",
journal = "Cell Growth and Differentiation",
issn = "1044-9523",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure

T2 - Spontaneously mutant selection

AU - Righetti, Sabina C.

AU - Perego, Paola

AU - Corna, Elisabetta

AU - Pierotti, Marco A.

AU - Zunino, Franco

PY - 1999/7

Y1 - 1999/7

N2 - We have previously shown that p53 mutations are associated with cisplatin resistance in ovarian carcinoma IGROV-1/Pt 1 cells. The relationship between p53 status and the development of resistance has not been completely elucidated; in particular, the biological mechanisms behind the acquired drug-resistant p53-mutant phenotype were not clearly explained. Thus, in this study, we investigated whether the p53 mutations found in IGROV-1/Pt 1 cells (270 and 282 codons) resulted from selection, under the selective pressure of the cytotoxic treatment, of a spontaneously mutant cell population preexistent in the cisplatin-sensitive parental cell line (IGROV- 1) or were induced by drug (genotoxic) treatment. For this purpose, an allele-specific PCR approach was used. Primers carrying the desired mutations (T→A codon 270, C→T codon 282) in the 3' terminus, and the corresponding wild-type primers were used to amplify genomic DNA from the original IGROV-1 cell line used to select the mutant IGROV-1/Pt 1. To increase sensitivity, we hybridized blots of the PCRs with the radiolabeled PCR fragment from IGROV- 1/Pt 1. Amplification was obtained for IGROV-1 DNA with the mutated allele- specific primers, indicating the preexistence of a mutated population in the IGROV-1 cell line. Titration experiments suggested that the frequency of the mutated alleles was

AB - We have previously shown that p53 mutations are associated with cisplatin resistance in ovarian carcinoma IGROV-1/Pt 1 cells. The relationship between p53 status and the development of resistance has not been completely elucidated; in particular, the biological mechanisms behind the acquired drug-resistant p53-mutant phenotype were not clearly explained. Thus, in this study, we investigated whether the p53 mutations found in IGROV-1/Pt 1 cells (270 and 282 codons) resulted from selection, under the selective pressure of the cytotoxic treatment, of a spontaneously mutant cell population preexistent in the cisplatin-sensitive parental cell line (IGROV- 1) or were induced by drug (genotoxic) treatment. For this purpose, an allele-specific PCR approach was used. Primers carrying the desired mutations (T→A codon 270, C→T codon 282) in the 3' terminus, and the corresponding wild-type primers were used to amplify genomic DNA from the original IGROV-1 cell line used to select the mutant IGROV-1/Pt 1. To increase sensitivity, we hybridized blots of the PCRs with the radiolabeled PCR fragment from IGROV- 1/Pt 1. Amplification was obtained for IGROV-1 DNA with the mutated allele- specific primers, indicating the preexistence of a mutated population in the IGROV-1 cell line. Titration experiments suggested that the frequency of the mutated alleles was

UR - http://www.scopus.com/inward/record.url?scp=0032803707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032803707&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 473

EP - 478

JO - Cell Growth and Differentiation

JF - Cell Growth and Differentiation

SN - 1044-9523

IS - 7

ER -